XML 78 R70.htm IDEA: XBRL DOCUMENT
v3.25.3

Share-Based Payments (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2025
Statements [Line Items] |
Summary of Total Expenses Arising From Share-based Payment Transactions | Total expenses arising from share-based payment transactions recognized during the period as part of employee benefit expense were as follows:
|  | Consolidated |
|  | June 30, 2025 A$ |  |  | June 30, 2024 A$ |
Employee share-based payment expense |  |  | 1,163,543 |  |  |  | 1,796,286 |
|  |  | 1,163,543 |  |  |  | 1,796,286 |
Executive Incentive Plan [member] | Performance rights [member] |
Statements [Line Items] |
Summaries of Performance Rights Granted | Fiscal year ended June 30, 2025
Grant date |  | Fair Value |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
November 26, 2021 |  |  | 0.490 |  |  |  | 3,600,000 |  |  |  | — |  |  |  | (2,400,000 | ) |  |  | — |  |  |  | 1,200,000 |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 4,500,000 |  |  |  | — |  |  |  | (3,000,000 | ) |  |  | — |  |  |  | 1,500,000 |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 1,933,333 |  |  |  | — |  |  |  | (966,667 | ) |  |  | — |  |  |  | 966,666 |  |  |  | — |
December 16, 2022 |  |  | 0.330 |  |  |  | 1,112,334 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,112,334 |  |  |  | 834,250 |
January 31, 2024 |  |  | 0.350 |  |  |  | 1,343,856 |  |  |  | — |  |  |  | — |  |  |  | (1,343,856 | ) |  |  | — |  |  |  | — |
January 31, 2024 |  |  | 0.350 |  |  |  | 1,381,012 |  |  |  | — |  |  |  | (460,338 | ) |  |  | (662,610 | ) |  |  | 258,064 |  |  |  | — |
November 22, 2024 |  |  | 0.305 |  |  |  | — |  |  |  | 2,700,000 |  |  |  | — |  |  |  | — |  |  |  | 2,700,000 |  |  |  | — |
November 22, 2024 |  |  | 0.305 |  |  |  | — |  |  |  | 3,600,000 |  |  |  | — |  |  |  | — |  |  |  | 3,600,000 |  |  |  | — |
November 22, 2024 |  |  | 0.305 |  |  |  | — |  |  |  | 3,200,000 |  |  |  | — |  |  |  | — |  |  |  | 3,200,000 |  |  |  | — |
December 5, 2024 |  |  | 0.310 |  |  |  | — |  |  |  | 1,700,000 |  |  |  | — |  |  |  | — |  |  |  | 1,700,000 |  |  |  | — |
Total |  |  |  |  |  |  | 13,870,535 |  |  |  | 11,200,000 |  |  |  | (6,827,005 | ) |  |  | (2,006,466 | ) |  |  | 16,237,064 |  |  |  | 834,250 |
Fiscal year ended June 30, 2024
|  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |
Grant date |  | Fair Value |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
October 1, 2021 |  |  | 0.550 |  |  |  | 17,699 |  |  |  | — |  |  |  | (17,699 | ) |  |  | — |  |  |  | — |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 3,600,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,600,000 |  |  |  | 1,200,000 |
November 26, 2021 |  |  | 0.490 |  |  |  | 4,500,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,500,000 |  |  |  | 1,500,000 |
November 26, 2021 |  |  | 0.490 |  |  |  | 2,900,000 |  |  |  | — |  |  |  | (966,667 | ) |  |  | — |  |  |  | 1,933,333 |  |  |  | — |
December 16, 2022 |  |  | 0.330 |  |  |  | 1,112,334 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,112,334 |  |  |  | 556,167 |
January 31, 2024 |  |  | 0.350 |  |  |  | — |  |  |  | 1,343,856 |  |  |  | — |  |  |  | — |  |  |  | 1,343,856 |  |  |  | — |
January 31, 2024 |  |  | 0.350 |  |  |  | — |  |  |  | 1,381,012 |  |  |  | — |  |  |  | — |  |  |  | 1,381,012 |  |  |  | — |
Total |  |  |  |  |  |  | 12,130,033 |  |  |  | 2,724,868 |  |  |  | (984,366 | ) |  |  | — |  |  |  | 13,870,535 |  |  |  | 3,256,167 |
Fiscal year ended June 30, 2023
|  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |  |  | $ |  |
Grant date |  | Fair value |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
October 3, 2019 |  |  | 0.260 |  |  |  | 1,500,000 |  |  |  | — |  |  |  | (1,500,000 | ) |  |  | — |  |  |  | — |  |  |  | — |
November 1, 2019 |  |  | 0.280 |  |  |  | 2,400,000 |  |  |  | — |  |  |  | (2,400,000 | ) |  |  | — |  |  |  | — |  |  |  | — |
January 2, 2020 |  |  | 0.260 |  |  |  | 1,400,000 |  |  |  | — |  |  |  | (1,400,000 | ) |  |  | — |  |  |  | — |  |  |  | — |
October 2, 2020 |  |  | 0.235 |  |  |  | 263,502 |  |  |  | — |  |  |  | (263,502 | ) |  |  | — |  |  |  | — |  |  |  | — |
October 1, 2021 |  |  | 0.550 |  |  |  | 206,404 |  |  |  | — |  |  |  | (188,705 | ) |  |  | — |  |  |  | 17,699 |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 3,600,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,600,000 |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 4,500,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,500,000 |  |  |  | — |
November 26, 2021 |  |  | 0.490 |  |  |  | 2,900,000 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,900,000 |  |  |  | — |
December 16, 2022 |  |  | 0.330 |  |  |  | — |  |  |  | 1,112,334 |  |  |  | — |  |  |  | — |  |  |  | 1,112,334 |  |  |  | — |
Total |  |  |  |  |  |  | 16,769,906 |  |  |  | 1,112,334 |  |  |  | (5,752,207 | ) |  |  | — |  |  |  | 12,130,033 |  |  |  | — |
Summary of STI Performance Rights Granted | The model inputs for STI performance rights granted during the fiscal year ended June 30, 2025 included:
|  | $ |  |  |  | $ |  |
Grant date |  | December 5, 2024 |  |  | November 22, 2024 |
Share price at grant date |  | $ | 0.31 |  |  | $ | 0.305 |
Expected price volatility of the Company’s shares |  |  | 63 | % |  |  | 63 | %
Expected dividend yield |  |  | Nil |  |  |  | Nil |
Risk-free interest rate |  |  | 3.88 | % |  |  | 4.2 | %
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2024 included:
|  | $ |  |  |  | $ |  |
Grant date |  | June 30, 2024* |  |  | January 31, 2024 |
Share price at grant date |  | $ | 0.295 |  |  | $ | 0.35 |
Expected price volatility of the Company’s shares |  |  | 62 | % |  |  | 58 | %
Expected dividend yield |  |  | Nil |  |  |  | Nil |
Risk-free interest rate |  |  | 4.19 | % |  |  | 3.68 | %
* | 3,147,952 performance rights due to vest on October 1, 2024, 3,147,952 performance rights due to vest on October 1, 2025 and 447,952 performance rights due to vest on October 1, 2026 have not met the definition of grant date under AASB 2 (IFRS 2)- Share Based payments. Accordingly, the share-based expense recogni z ed was using an estimate of the grant date fair value at June 30, 2024. The value will be re-assessed at each reporting date until grant date has been identified. For all tranches, the vesting conditions consist of service-based vesting conditions subject to certain defined corporate Key Performance Indicators (KPIs). The performance rights will expire, if not exercised, five years from the date of issue. There are no outstanding options under EIP at the beginning of the financial year 2024 and no option was granted during the year ended June 30, 2024.
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2023 included:
Grant date |  | June 30, 2023* |
Share price at grant date |  | $ | 0.275 |
Expected price volatility of the Company’s shares |  |  | 60 | %
Expected dividend yield |  |  | Nil |
Risk-free interest rate |  |  | 3.40 | %
* | 2,700,000 performance rights due to vest on October 1, 2024 and 2,700,000 performance rights due to vest on October 1, 2025 have not met the definition of grant date under AASB 2(IFRS2) - Share Based payments. Accordingly, the share-based expense recogni z ed was using an estimate of the grant date fair value at June 30, 2023. The value will be re-assessed at each reporting date until grant date has been identified. For all tranches, the vesting conditions consist of service-based vesting conditions subject to certain defined corporate Key Performance Indicators (KPIs). The performance rights will expire, if not exercised, five years from the date of issue. There are no outstanding options under EIP at the beginning of the fiscal year 2023 and no option was granted during the year ended June 30, 2023.
Directors Incentive Plan [member] | Performance rights [member] |
Statements [Line Items] |
Summaries of Performance Rights Granted | Fiscal year ended 30 June 2025
2025 Grant date |  | Type of Performance right granted |  |  | Fair Value* |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
November 23, 2022 |  |  | Director rights |  |  |  | 0.310 |  |  |  | 1,166,667 |  |  |  | — |  |  |  | (388,889 | ) |  |  | — |  |  |  | 777,778 |  |  |  | — |
December 1, 2021 |  |  | Director rights |  |  |  | 0.490 |  |  |  | 226,414 |  |  |  | — |  |  |  | (226,414 | ) |  |  | — |  |  |  | — |  |  |  | — |
October 24, 2023 |  |  | Director rights |  |  |  | 0.320 |  |  |  | 178,356 |  |  |  | — |  |  |  | (78,356 | ) |  |  | — |  |  |  | 100,000 |  |  |  | — |
October 24, 2023 |  |  | Director rights |  |  |  | 0.320 |  |  |  | 589,955 |  |  |  | — |  |  |  | (256,621 | ) |  |  | — |  |  |  | 333,334 |  |  |  | — |
Total |  |  |  |  |  |  |  |  |  |  | 2,161,392 |  |  |  | — |  |  |  | (950,280 | ) |  |  | — |  |  |  | 1,211,112 |  |  |  | — |
* | The weighted average share price on the exercising date during the financial year 2025 is $0.332.
Fiscal year ended 30 June 2024
2024 Grant date |  | Type of Performance right granted |  |  | Fair Value* |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
November 1, 2019 |  |  | Director rights |  |  |  | 0.280 |  |  |  | 500,000 |  |  |  | — |  |  |  | (500,000 | ) |  |  | — |  |  |  | — |  |  |  | — |
November 23, 2022 |  |  | Director rights |  |  |  | 0.310 |  |  |  | 1,166,667 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,166,667 |  |  |  | — |
December 1, 2021 |  |  | Director rights |  |  |  | 0.490 |  |  |  | 226,414 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 226,414 |  |  |  | 113,207 |
October 24, 2023 |  |  | Director rights |  |  |  | 0.320 |  |  |  | — |  |  |  | 178,356 |  |  |  | — |  |  |  | — |  |  |  | 178,356 |  |  |  | 28,356 |
October 24, 2023 |  |  | Director rights |  |  |  | 0.320 |  |  |  | — |  |  |  | 589,955 |  |  |  | — |  |  |  | — |  |  |  | 589,955 |  |  |  | 89,954 |
Total |  |  |  |  |  |  |  |  |  |  | 1,893,081 |  |  |  | 768,311 |  |  |  | (500,000 | ) |  |  | — |  |  |  | 2,161,392 |  |  |  | 231,517 |
The weighted average share price on the exercising date during the financial year 2024 is $0.285. Fiscal year ended 30 June 2023
2023 Grant date |  | Type of performance right granted |  |  | Fair Value* |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Lapsed during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
November 1, 2019 |  |  | Director rights |  |  |  | 0.280 |  |  |  | 1,000,000 |  |  |  | — |  |  |  | (500,000 | ) |  |  | — |  |  |  | 500,000 |  |  |  | — |
November 23, 2022 |  |  | Director rights |  |  |  | 0.310 |  |  |  | — |  |  |  | 1,166,667 |  |  |  | — |  |  |  | — |  |  |  | 1,166,667 |  |  |  | — |
December 1, 2021 |  |  | Director rights |  |  |  | 0.490 |  |  |  | 339,621 |  |  |  | — |  |  |  | (113,207 | ) |  |  | — |  |  |  | 226,414 |  |  |  | — |
November 23, 2022 |  |  | Director rights |  |  |  | 0.310 |  |  |  | — |  |  |  | 457,832 |  |  |  | (92,966 | ) |  |  | (364,866 | )* |  |  | — |  |  |  | — |
Total |  |  |  |  |  |  |  |  |  |  | 1,339,621 |  |  |  | 1,624,499 |  |  |  | (706,173 | ) |  |  | (364,866 | ) |  |  | 1,893,081 |  |  |  | — |
* | The change during the year represents derecognition due to the cessation of the director.
Summary of STI Performance Rights Granted | The model inputs for STI performance rights granted during the fiscal year ended June 30, 2024 included:
|  | $ |  |  |  | $ |  |
Grant date |  | June 30, 2024* |  |  | October 24, 2023 |
Share price at grant date |  | $ | 0.295 |  |  | $ | 0.32 |
Expected price volatility of the Company’s shares |  |  | 62 | % |  |  | 56 | %
Expected dividend yield |  |  | Nil |  |  |  | Nil |
Risk-free interest rate |  |  | 4.11 | % |  |  | 4.3 | %
* | Director performance rights granted during the year ended June 30, 2024 have not met the definition of grant date under AASB 2(IFRS 2) - Share Based payments. Accordingly, the share-based expense recognized was using an estimate of the grant date fair value at June 30, 2024. The value will be re-assessed at the next reporting date as the grant date will be the 2024 AGM date.
The model inputs for STI performance rights granted during the fiscal year ended June 30, 2023 included:
|  | $ |  |  |  | $ |  |
Grant date |  | June 30, 2023* |  |  | November 23, 2022 |
Share price at grant date |  | $ | 0.315 |  |  | $ | 0.310 |
Expected price volatility of the Company’s shares |  |  | 75 | % |  |  | 75 | %
Expected dividend yield |  |  | Nil |  |  |  | Nil |
Risk-free interest rate |  |  | 3.94 | % |  |  | 3.4 | %
* | Director performance rights granted during the year ended June 30, 2023 have not met the definition of grant date under AASB 2 (IFRS 2) - Share Based payments. Accordingly, the share-based expense recogni z ed was using an estimate of the grant date fair value at June 30, 2023. The value will be re-assessed at the next reporting date as the grant date will be the 2023 AGM date.
Ridgeback Capital Investments and Trout Group LLC. [member] | Stock Option 1 [member] |
Statements [Line Items] |
Summaries of Options Granted | Set out below is a summary of the options granted to both parties:
2024 Grant date |  | Expiry date |  |  | Exercise price |  |  | Balance at start of the fiscal year Number |  |  | Granted during the fiscal year Number |  |  | Exercised during the fiscal year Number |  |  | Forfeited during the fiscal year Number |  |  | Balance at end of the fiscal year Number |  |  | Vested and exercisable at end of the fiscal year Number |
July 31, 2015 |  |  | August 5, 2025 |  |  |  | 0.248 |  |  |  | 847,600 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 847,600 |  |  |  | — |
Total |  |  |  |  |  |  |  |  |  |  | 847,600 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 847,600 |  |  |  | — |

X
- Definition The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2025-01-01 -Paragraph 45 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 31 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 31 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of expense from share-based payment arrangements. + References No definition available. + Details
Name: | immp_DisclosureOfExpenseFromSharebasedPaymentArrangementsExplanatory
Namespace Prefix: | immp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of model inputs for short term incentive performance rights granted. + References No definition available. + Details
Name: | immp_DisclosureOfModelInputsForShortTermIncentivePerformanceRightsGrantedExplanatory
Namespace Prefix: | immp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of performance rights granted explanatory. + References No definition available. + Details
Name: | immp_DisclosureOfPerformanceRightsGrantedExplanatory
Namespace Prefix: | immp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | immp_StatementsLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | immp_PlanName1Axis=immp_ExecutiveIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=immp_PerformanceRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | immp_PlanName1Axis=immp_DirectorsIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=immp_RidgebackCapitalInvestmentsAndTroutGroupLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=immp_StockOption1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |